- Home
- PETZ vs NERV Comparison
PETZ vs NERV Comparison
Compare PETZ & NERV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PETZ
- NERV
- Stock Information
- Founded
- PETZ 2002
- NERV 2007
- Country
- PETZ China
- NERV United States
- Employees
- PETZ N/A
- NERV N/A
- Industry
- PETZ Steel/Iron Ore
- NERV Biotechnology: Pharmaceutical Preparations
- Sector
- PETZ Industrials
- NERV Health Care
- Exchange
- PETZ Nasdaq
- NERV Nasdaq
- Market Cap
- PETZ 12.9M
- NERV 10.7M
- IPO Year
- PETZ 2017
- NERV 2014
- Fundamental
- Price
- PETZ $1.10
- NERV $1.44
- Analyst Decision
- PETZ
- NERV Hold
- Analyst Count
- PETZ 0
- NERV 1
- Target Price
- PETZ N/A
- NERV $5.00
- AVG Volume (30 Days)
- PETZ 8.7K
- NERV 15.7K
- Earning Date
- PETZ 04-28-2025
- NERV 04-30-2025
- Dividend Yield
- PETZ N/A
- NERV N/A
- EPS Growth
- PETZ N/A
- NERV N/A
- EPS
- PETZ N/A
- NERV 0.19
- Revenue
- PETZ $3,278,453.00
- NERV N/A
- Revenue This Year
- PETZ N/A
- NERV N/A
- Revenue Next Year
- PETZ N/A
- NERV N/A
- P/E Ratio
- PETZ N/A
- NERV $8.63
- Revenue Growth
- PETZ 2.46
- NERV N/A
- 52 Week Low
- PETZ $1.03
- NERV $1.42
- 52 Week High
- PETZ $1.74
- NERV $3.69
- Technical
- Relative Strength Index (RSI)
- PETZ 40.27
- NERV 33.73
- Support Level
- PETZ $1.10
- NERV $1.52
- Resistance Level
- PETZ $1.20
- NERV $1.80
- Average True Range (ATR)
- PETZ 0.07
- NERV 0.12
- MACD
- PETZ -0.02
- NERV -0.02
- Stochastic Oscillator
- PETZ 18.97
- NERV 29.14
About PETZ TDH Holdings Inc.
TDH Holdings Inc is engaged in the business of manufacturing and selling of petfood and restaurant operations. The company has two operating segments which include Petfood sales and Restaurant business. It has a focus on the Restaurant business segment and generates the majority of its revenue.
About NERV Minerva Neurosciences Inc
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.